212 related articles for article (PubMed ID: 35250882)
1. Effects of SGLT-2 Inhibitors on Vascular Endothelial Function and Arterial Stiffness in Subjects With Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Wei R; Wang W; Pan Q; Guo L
Front Endocrinol (Lausanne); 2022; 13():826604. PubMed ID: 35250882
[TBL] [Abstract][Full Text] [Related]
2. Effects of Newer Antidiabetic Drugs on Endothelial Function and Arterial Stiffness: A Systematic Review and Meta-Analysis.
Batzias K; Antonopoulos AS; Oikonomou E; Siasos G; Bletsa E; Stampouloglou PK; Mistakidi CV; Noutsou M; Katsiki N; Karopoulos P; Charalambous G; Thanopoulou A; Tentolouris N; Tousoulis D
J Diabetes Res; 2018; 2018():1232583. PubMed ID: 30622967
[TBL] [Abstract][Full Text] [Related]
3. Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatment.
Ikonomidis I; Pavlidis G; Thymis J; Birba D; Kalogeris A; Kousathana F; Kountouri A; Balampanis K; Parissis J; Andreadou I; Katogiannis K; Dimitriadis G; Bamias A; Iliodromitis E; Lambadiari V
J Am Heart Assoc; 2020 May; 9(9):e015716. PubMed ID: 32326806
[TBL] [Abstract][Full Text] [Related]
4. Effect of sodium-glucose co-transporter-2 inhibitors on arterial stiffness: A systematic review and meta-analysis of randomized controlled trials.
Patoulias D; Papadopoulos C; Kassimis G; Fragakis N; Vassilikos V; Karagiannis A; Doumas M
Vasc Med; 2022 Oct; 27(5):433-439. PubMed ID: 35754338
[TBL] [Abstract][Full Text] [Related]
5. Comparative effects of glucose-lowering agents on endothelial function and arterial stiffness in patients with type 2 diabetes: A network meta-analysis.
Kim H; Choi CU; Rhew K; Park J; Lim Y; Kim MG; Kim K
Atherosclerosis; 2024 Apr; 391():117490. PubMed ID: 38452432
[TBL] [Abstract][Full Text] [Related]
6. Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials.
Patoulias D; Stavropoulos K; Imprialos K; Katsimardou A; Kalogirou MS; Koutsampasopoulos K; Zografou I; Papadopoulos C; Karagiannis A; Doumas M
Diabetes Res Clin Pract; 2019 Dec; 158():107927. PubMed ID: 31733280
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis.
Li CX; Liang S; Gao L; Liu H
PLoS One; 2021; 16(2):e0244689. PubMed ID: 33606705
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular Outcomes with SGLT-2 inhibitors in patients with heart failure with or without type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
Singh AK; Singh R
Diabetes Metab Syndr; 2021; 15(1):351-359. PubMed ID: 33503584
[TBL] [Abstract][Full Text] [Related]
9. Relationship Between SGLT-2i and Ocular Diseases in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials.
Zhou B; Shi Y; Fu R; Ni H; Gu L; Si Y; Zhang M; Jiang K; Shen J; Li X; Sun X
Front Endocrinol (Lausanne); 2022; 13():907340. PubMed ID: 35692406
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of SGLT-2i in overweight/obese, non-diabetic individuals: a meta-analysis of randomized controlled trials.
Shi Y; Si Y; Fu R; Zhang M; Jiang K; Dai W; Shen J; Li X; Yuan Y
Endokrynol Pol; 2022; 73(1):71-80. PubMed ID: 35119088
[TBL] [Abstract][Full Text] [Related]
11. SGLT-2i and Risk of Malignancy in Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials.
Shi N; Shi Y; Xu J; Si Y; Yang T; Zhang M; Ng DM; Li X; Xie F
Front Public Health; 2021; 9():668368. PubMed ID: 34164370
[No Abstract] [Full Text] [Related]
12. Pre-admission use of sodium glucose transporter-2 inhibitor (SGLT-2i) may significantly improves Covid-19 outcomes in patients with diabetes: A systematic review, meta-analysis, and meta-regression.
Permana H; Audi Yanto T; Ivan Hariyanto T
Diabetes Res Clin Pract; 2023 Jan; 195():110205. PubMed ID: 36502891
[TBL] [Abstract][Full Text] [Related]
13. Effects of sodium-glucose cotransporter type 2 inhibitors on cardiovascular, renal, and safety outcomes in patients with cardiovascular disease: a meta-analysis of randomized controlled trials.
Zheng C; Lin M; Chen Y; Xu H; Yan L; Dai H
Cardiovasc Diabetol; 2021 Apr; 20(1):83. PubMed ID: 33888126
[TBL] [Abstract][Full Text] [Related]
14. Sodium Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Hospitalization in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Zhang A; Luo X; Meng H; Kang J; Qin G; Chen Y; Zhang X
Front Endocrinol (Lausanne); 2020; 11():604250. PubMed ID: 33519713
[TBL] [Abstract][Full Text] [Related]
15. Effect of sodium-glucose cotransporter 2 inhibitors on the rate of decline in kidney function: A systematic review and meta-analysis.
Duo Y; Gao J; Yuan T; Zhao W
J Diabetes; 2023 Jan; 15(1):58-70. PubMed ID: 36610036
[TBL] [Abstract][Full Text] [Related]
16. Sodium Glucose Cotransporter Type 2 Inhibitors Improve Cardiorenal Outcome of Patients With Coronary Artery Disease: A Meta-Analysis.
Wei W; Liu J; Chen S; Xu X; Guo D; He Y; Huang Z; Wang B; Huang H; Li Q; Chen J; Chen H; Tan N; Liu Y
Front Endocrinol (Lausanne); 2022; 13():850836. PubMed ID: 35330914
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study.
Kosiborod M; Lam CSP; Kohsaka S; Kim DJ; Karasik A; Shaw J; Tangri N; Goh SY; Thuresson M; Chen H; Surmont F; Hammar N; Fenici P;
J Am Coll Cardiol; 2018 Jun; 71(23):2628-2639. PubMed ID: 29540325
[TBL] [Abstract][Full Text] [Related]
18. Comparing SGLT-2 inhibitors to DPP-4 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes: A systematic review and meta-analysis.
Mishriky BM; Tanenberg RJ; Sewell KA; Cummings DM
Diabetes Metab; 2018 Mar; 44(2):112-120. PubMed ID: 29477373
[TBL] [Abstract][Full Text] [Related]
19. Does background metformin therapy influence the cardiovascular outcomes with SGLT-2 inhibitors in type 2 diabetes?
Singh AK; Singh R
Diabetes Res Clin Pract; 2021 Feb; 172():108536. PubMed ID: 33181201
[TBL] [Abstract][Full Text] [Related]
20. Effects of Antidiabetic Drugs on Endothelial Function in Patients With Type 2 Diabetes Mellitus: A Bayesian Network Meta-Analysis.
Wang Y; Yao M; Wang J; Liu H; Zhang X; Zhao L; Hu X; Guan H; Lyu Z
Front Endocrinol (Lausanne); 2022; 13():818537. PubMed ID: 35370959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
